TNI BioTech Out-licenses Two Drugs to Hubei Qianjiang Pharma

TNI BioTech of the US has out-licensed the China rights for two R&D-stage cancer treatments to Hubei Qianjiang Pharma. TNI’s technology centers on methionine enkephalin (MENK), a cytokine that stimulates the immune system. In IRT-101, MENK is infused directly into the patient. In IRT-102, the treatment consists of isolating a patient's lymphocytes, incubating them with MENK, and the re-infusing them to fight tumor cells. More details.... Stock Symbols: (PINKSHEETS: TNIB) (SHA: 600568) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});